GLP-1 and Lean Muscle Loss: What the Research Says and How to Fight Back

Here’s a number that should give every man on a GLP-1 medication pause: up to 40% of the weight lost during GLP-1 receptor agonist therapy can come from lean body mass — not fat. That figure, drawn from recent clinical data cited in a 2025 review in Current Nutrition Reports, reframes what is otherwise a remarkable pharmacological success story. Semaglutide and tirzepatide have genuinely transformed metabolic medicine, helping men shed 15 to 25 percent of their total body weight in ways that were previously achievable only through bariatric surgery. But the scale going down isn’t the whole story — what’s actually leaving the body matters enormously, and right now, too much of it is muscle.

Skeletal muscle isn’t just aesthetically important. It is the primary driver of your resting metabolic rate, the tissue most responsible for glucose disposal, and the physiological buffer between healthy aging and what researchers call sarcopenic obesity — a state where fat accumulates as muscle wastes, compounding metabolic dysfunction in ways that are genuinely difficult to reverse. A 2024 analysis in Metabolism: Clinical and Experimental from Stefanakis, Kokkorakis, and Mantzoros makes this point plainly: losing muscle during weight loss — whether from surgery, pharmacotherapy, or aggressive dieting — impairs metabolic rate, compromises physical function, and significantly raises the risk of sarcopenic obesity down the road. For older men, or those already carrying metabolic risk factors, the stakes are even higher.

The mechanism behind this muscle loss isn’t mysterious. GLP-1 receptor agonists work primarily by suppressing appetite and slowing gastric emptying, which creates a significant caloric deficit. That deficit is powerful — it’s why these drugs produce such dramatic weight loss. But as Rossi, Bucciarelli, and colleagues writing in Acta Diabetologica in 2026 explain, the combination of chronic caloric restriction, reduced physical activity from lower energy availability, and the underlying metabolic dysfunction common in obesity creates a perfect environment for muscle catabolism. Inflammation, mitochondrial dysfunction, and altered protein metabolism — all hallmarks of metabolic disease — make men on these medications particularly vulnerable to accelerated muscle wasting. The drug itself isn’t directly destroying muscle, but the conditions it creates, left unmanaged, absolutely can.

The Biological Tug-of-War Inside Your Muscle Tissue

To understand how to protect your muscle during GLP-1-driven weight loss, you need to understand what’s regulating muscle growth and breakdown at the molecular level. The key players are a group of signaling proteins — myostatin, activin A, and follistatin — that act as biological switches governing whether your body builds or breaks down skeletal muscle. Myostatin and activin A function as brakes on muscle growth, signaling through what are called activin type II receptors (ActRII) to suppress hypertrophy. Follistatin, by contrast, inhibits myostatin and activins, effectively releasing the brake and allowing muscle to grow. In states of significant caloric deficit — exactly the state GLP-1 medications induce — the balance tilts heavily toward the myostatin and activin side, promoting muscle degradation over preservation.

This biological reality has driven serious pharmaceutical research. A landmark 2024 study published in Molecular Metabolism by Nunn, Jaiswal, Gavin, and colleagues tested what happens when you block ActRII signaling in animals receiving semaglutide. The results were striking. Bimagrumab, a monoclonal antibody that blocks activin type II receptors, induced roughly a 10 percent increase in lean mass in obese mice while simultaneously decreasing fat mass. When combined with semaglutide, the combination produced superior fat loss compared to semaglutide alone — while fully preserving lean mass despite the substantial reduction in food intake. The animals also showed improved metabolic outcomes and better exercise performance, outcomes that are directly tied to the preservation of functional muscle tissue.

The same 2024 review from Stefanakis and Mantzoros highlights that bimagrumab isn’t alone in this space. Trevogrumab and garetosmab — both targeting myostatin and activin signaling — are also in development pipelines and have shown early promise in clinical settings. These aren’t fringe compounds; they represent a serious pharmacological strategy being pursued specifically because the field recognizes that fat loss without muscle preservation is an incomplete therapeutic win. As Pantazopoulos, Gouveri, and Papazoglou noted in a 2025 review in Diabetes Research and Clinical Practice, blocking growth differentiation factor-8 (GDF8, the gene encoding myostatin) and activin A represents one of the most promising emerging strategies for preventing sarcopenia in men taking GLP-1-based therapies. Most of these combination approaches are still in trials, however, which means the practical burden of muscle preservation falls squarely on the man himself — through protein intake, resistance training, and strategic lifestyle management.

What Actually Works: The Non-Negotiable Pillars of Muscle Preservation

The research on this is consistent, and it deserves to be stated plainly: the two most powerful tools available to any man trying to preserve muscle during weight loss — whether on GLP-1 medications or not — are adequate dietary protein and resistance training. These are not suggestions. They are physiological requirements.

On the protein side, the challenge for GLP-1 users is that appetite suppression makes hitting meaningful protein targets genuinely difficult. When you’re eating 1,200 to 1,600 calories a day and barely hungry, protein often gets crowded out by whatever is most palatable. But the 2025 review in Current Nutrition Reports is explicit: a high protein diet, combined with resistance training, is currently the most evidence-supported strategy for minimizing lean mass loss during GLP-1 therapy. For practical purposes, men on calorie-restricted diets should be targeting a minimum of 1.6 grams of protein per kilogram of body weight daily — and many researchers in this space argue for 2.0 grams or higher when the deficit is significant. This means prioritizing protein at every meal, treating it as the non-negotiable anchor of the plate before anything else is added. Lean meats, eggs, Greek yogurt, cottage cheese, and high-quality protein supplements all serve this function. The specific source matters less than the consistency of hitting the target.

Resistance training works through a fundamentally different but complementary mechanism. When you place mechanical stress on muscle through progressive overload, you trigger anabolic signaling pathways — mTOR, IGF-1, and others — that counteract the catabolic signals running in the background during caloric restriction. The myostatin-activin system is partially suppressed by mechanical loading, which is part of why trained men lose significantly less muscle during dieting than untrained men eating the same calories. You don’t need to train like a competitive bodybuilder to benefit here. Three to four sessions of full-body or upper/lower split resistance training per week, using compound movements like squats, deadlifts, rows, and presses, is sufficient to meaningfully blunt muscle loss during a deficit. The key is consistent progressive overload — giving the body a reason to hold onto muscle even when the caloric environment is telling it not to.

Sleep and stress management are less discussed but mechanistically important. Cortisol — the primary stress hormone — is directly catabolic to muscle tissue, and chronically elevated cortisol during aggressive dieting compounds the muscle loss problem substantially. Men getting fewer than seven hours of quality sleep per night show measurably higher rates of lean mass loss during caloric restriction compared to those sleeping adequately, a finding with real practical implications. Optimizing sleep, managing psychological stress, and not simultaneously pursuing extreme training volume and extreme caloric restriction all reduce the catabolic load on muscle tissue.

Creatine monohydrate deserves a specific mention in this context because its evidence base is unusually robust for a supplement. Creatine supports phosphocreatine resynthesis during high-intensity exercise, increases training performance and volume capacity, and has shown direct effects on muscle hydration and cross-sectional area independent of training. In men pursuing significant weight loss — especially older men at elevated sarcopenia risk — creatine is one of the few supplements where the risk-to-benefit calculation is clearly favorable. Three to five grams per day, consistently, is the studied dose.

The Takeaway

GLP-1 medications represent a genuine breakthrough in obesity medicine, and the men using them are making a legitimate investment in their metabolic health. But the research is now clear that weight loss and fat loss are not the same thing, and that losing significant lean mass in the process undermines the very metabolic improvements these drugs are meant to provide. The emerging pharmacology — ActRII blockade with bimagrumab and similar agents — points toward a future where combination therapy can produce superior fat loss with full muscle preservation. That future isn’t fully here yet for most men.

What is here, right now, is a well-established playbook: eat enough protein to support muscle protein synthesis, lift weights with enough frequency and intensity to give your body a structural reason to hold onto muscle, sleep adequately, and manage the catabolic stress load. These aren’t GLP-1-specific recommendations — they are the universal requirements for any man who wants his weight loss to actually improve his body composition rather than simply make him lighter and frailer. The drug, the diet, or the deficit is only as good as the muscle it leaves behind.